Bond Oracle HER2 IHC System
Overview
The Bond Oracle HER2 IHC System is a fully-automated assay to accurately determine HER2 oncoprotein status in breast and gastric cancer tissue as an aid in the assessment of patients for whom Herceptin® (trastuzumab) treatment is being considered.
- Accurate - optimized to precisely separate 1+ and 2+ cases gives you excellent FISH concordance, reducing avoidable FISH requests.
- Drive Consistency - standardized protocols for uniform staining, decreased process variation, and consistent results.
- Maximize Efficiency - full automation frees up your skilled staff for other high-value tasks.
- A Complete Solution - integrated ready-to-use reagents, control slides, and advanced automation ensure quality and consistency.
For In Vitro Diagnostic Use
Features
Diagnostic Confidence
With treatment decisions dependent on a stained slide, you need confidence that your HER2 staining for breast and gastric cancer is consistent and accurate. The Bond Oracle HER2 IHC System gives you the assurance that comes with demonstrated HER2 FISH concordance and complete assay validation.
With the Oracle system, you get the accurate results needed for effective patient management.
Laboratory Efficiency
‘Go Lean’ without increasing resources. The Bond Oracle HER2 IHC System and the fully automated BOND-MAX and BOND-III staining platforms improve the efficiency of your laboratory with increased productivity and walk-away convenience.